Spero Therapeutics to report Q1 2026 financial results and business update on May 13

Spero Therapeutics, a clinical-stage biopharmaceutical company, will announce its financial results for the first quarter ending March 31, 2026, on May 13 after market close. The company will also provide a business update but will not hold a conference call. This report follows their recent activities including the resubmission of a New Drug Application for tebipenem HBr to the FDA. Investors should watch for insights on the company's progress in developing treatments for rare and high-need diseases.